Psychopharmacology of Psychiatric Disorders and Food Intake DOI
Samar F. Darwish, Sherif S. Abdel Mageed,

Ahmed Amr Raouf

и другие.

Опубликована: Янв. 1, 2024

Язык: Английский

The chronic unpredictable mild stress (CUMS) Paradigm: Bridging the gap in depression research from bench to bedside DOI

Shweta Sharma,

Shivani Chawla,

Praveen Kumar

и другие.

Brain Research, Год журнала: 2024, Номер 1843, С. 149123 - 149123

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

11

Gut dysbiosis, anxiety and depression and the neurotoxic effects of formulated favipiravir and the restorative impact of vitamin D supplementation in adult zebrafish DOI

Ipshita Mukherjee,

Ramasamy Vasantharekha, Barathi Seetharaman

и другие.

Journal of Food Science and Technology, Год журнала: 2025, Номер unknown

Опубликована: Март 12, 2025

Язык: Английский

Процитировано

0

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity DOI Creative Commons
Daniel A Kinderlehrer

Neuropsychiatric Disease and Treatment, Год журнала: 2025, Номер Volume 21, С. 141 - 155

Опубликована: Янв. 1, 2025

The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient mushrooms Psilocybe genus, both potent serotonin agonist anti-inflammatory agent, increases neuroplasticity, decreases overactivity default mode network. Studies using hallucinogenic doses psilocin under supervision therapist/guide consistently benefits individuals with depression end-of-life anxiety. Microdosing psilocybin sub-hallucinogenic has also mood disorders, may offer safe, less expensive, more available alternative full for as well other medical conditions which inflammation principal pathophysiology.

Язык: Английский

Процитировано

0

The Impact of Seasonality on Mental Health Disorders: A Narrative Review and Extension of the Immunoseasonal Theory DOI Open Access
Stefan Modzelewski,

Maciej Naumowicz,

Maria Suprunowicz

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(4), С. 1119 - 1119

Опубликована: Фев. 9, 2025

The impact of weather on mental illness is widely debated, but the mechanism this relationship remains unclear. immunoseasonal theory suggests that in winter, a T-helper 1 (Th1) response predominates, impairing Prefrontal Cortex (PFC) control, which exacerbates symptoms depression, while after it, summer, Th2 predominates immunologically prone individuals, activating cortical and mesolimbic centers, can exacerbate psychosis. In paper, we aim to describe validity through narrative review data related immunology psychiatry. This extends existing literature by integrating immunological findings with psychiatric seasonality research, offering mechanistic perspective links Th1/Th2 shifts specific symptom exacerbations. Winter Th1 severity may worsen depression anxiety, summer dominance appears be associated exacerbations schizophrenia, mania, impulsivity, suicide risk. It possible potentiation deterioration PFC function common most entities nonspecific. seasonal immune dysregulation play broader role disorders than previously recognized, challenging idea impacts only selected conditions. Characteristic dysfunctions within an individual determine further differences clinical manifestations. not limited mania psychosis also increased impulsivity If confirmed, markers could used diagnosis predicting fluctuations tailoring treatment strategies. enable more personalized interventions, such as seasonally adjusted medication dosing or targeted anti-inflammatory therapies. While seems plausible, especially analyzing inflammatory responses, needed better understand confirm it.

Язык: Английский

Процитировано

0

The Exciting Frontier of Neuroplasticity: Innovations in Brain Health and Recovery DOI Open Access
Ramendra N. Saha

Journal of Behavioral and Brain Science, Год журнала: 2025, Номер 15(03), С. 47 - 80

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

A Randomized Controlled Trial Comparing the Effects of Vilazodone, Escitalopram, and Vortioxetine Monotherapy on the Metabolic Parameters in Patients With Major Depressive Disorder DOI Open Access

N Simple Santi,

Sashi Bhusan Biswal,

Birendra Narayan Naik

и другие.

Cureus, Год журнала: 2024, Номер unknown

Опубликована: Авг. 27, 2024

The coexistence of major depressive disorder (MDD) and metabolic illness could culminate in an aberrant profile. Individuals with MDD type 2 diabetes mellitus (T2DM) are more likely to have impaired indicators. Effective antidepressant therapy can alleviate symptoms abnormalities. We focused on the effects vilazodone, escitalopram, vortioxetine indices. Our research aimed examine changes after 16 weeks intervention glycemic indices, serum creatinine, lipid profile, hepatic parameters, Hamilton Depression Rating Scale (HDRS) 17-item version.

Язык: Английский

Процитировано

1

Targeting Toll-like Receptor 4/Nuclear Factor-κB and Nrf2/Heme Oxygenase-1 Crosstalk via Trimetazidine Alleviates Lipopolysaccharide-Induced Depressive-like Behaviors in Mice DOI Creative Commons
Sarah S. Mohamed,

Nora O. Abdel Rasheed,

Weam W. Ibrahim

и другие.

Journal of Neuroimmune Pharmacology, Год журнала: 2024, Номер 19(1)

Опубликована: Сен. 23, 2024

Язык: Английский

Процитировано

1

Psychopharmacology of Psychiatric Disorders and Food Intake DOI
Samar F. Darwish, Sherif S. Abdel Mageed,

Ahmed Amr Raouf

и другие.

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0